Skip to main content
. 2020 Jul 23;8(3):408. doi: 10.3390/vaccines8030408

Figure 1.

Figure 1

Prediction of binding of antiviral peptides to MHC-I allotypes. (A) Distributions of the predicted affinities (IC50, log scale) to HLA-A and HLA-B supertypes of all possible linear 8- to 11-mer peptides derived from the 26 proteins of the SARS-CoV-2 proteome. The predicted MHC class I binding epitopes were classified as strong MHC binders (IC50 ≤ 50 nM), weak binders (50 nM < IC50 ≤ 500 nM) and non-binders (IC50 > 500 nM); (B) Number of MHC-I–binding 9- and 10-mers categorized as strong, weak and non-binders; (C) Number of 9-mer epitopes with an immunogenicity score ≥ 0.25 in SARS-CoV-2 proteins identified with the IEDB and NetCTL1.2 prediction methods.